CD274 and nonpapillary renal cell carcinoma: For the purpose of promotion in immunotherapy in ccRCC patients, based on three Immune-related cohorts (the Nivolumab group of the CheckMate 025 study, the Atezolizumab arm of IMmotion150 and the Atezolizumab plus Bevacizumab group of the IMmotion151 cohort), results indicated that high-risk group had a significantly lower response to anti-PD-1/PD-L1 therapy.